Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07416123 · ClinicalTrials.gov registry record · Phase 1

A Study of GEN1106 in Participants With Solid Tumors

A Phase 1 study of Solid Tumors and Urothelial Carcinoma, sponsored by Genmab.

Recruiting
Registry status
Phase 1
Development phase
103
Enrollment target
3
Study locations

NCT07416123 is a Phase 1 study of Solid Tumors and Urothelial Carcinoma that is actively recruiting participants, run by Genmab. The registered enrollment target is 103 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (64% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07416123, a Phase 1 study of Solid Tumors and Urothelial Carcinoma, is actively recruiting participants, sponsored by Genmab.

RECRUITING
Registry status
Phase 1
Development phase
103 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this trial is to learn about the safety and effectiveness of GEN1106 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1106 to find out if it is safe and determine what are the best doses to use. The second and third parts continues to test the safety of and how well GEN1106 works in additional participants with a specific cancer type and at doses chosen based on results from the first part of the trial. For each participant, the trial will last approximately 17 months but will vary for each person. This includes up to 21 days for screening prior to receiving trial treatment, approximately 5 months of treatment (the duration of treatment may vary for each participant), and approximately 11 months of follow up after trial treatment ends (the duration of follow up may vary for each participant). Participation in the trial will require visits to the site, with more frequent visits during the first 6 weeks of treatment and then less frequent visits afterwards. At site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, computed tomography \[CT\] scans) to monitor whether the treatment is safe and effective. All participants will receive active drug; no one will be given placebo.

Conditions Studied

Solid Tumors Urothelial Carcinoma

Interventions

  • BIOLOGICAL GEN1106

Study Locations (3)

New York

  • START New York Long Island LLC - Lake Success

South Carolina

  • Carolina Urologic Research Center - Myrtle Beach

Texas

  • South Texas Accelerated Research Therapeutics - San Antonio

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2026-03
Est. Completion 2029-06-25
Phase Phase 1

Sponsor

Genmab

45 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07416123

The ClinicalTrials.gov registry entry for NCT07416123 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (64% lower). The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which GEN1106 is the first listed.

NCT07416123 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, South Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT07416123 about?

NCT07416123 is a clinical study titled "A Study of GEN1106 in Participants With Solid Tumors". The purpose of this trial is to learn about the safety and effectiveness of GEN1106 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1106 to find out if it is safe and determine what...

What is the current status of trial NCT07416123?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2026-03. Estimated completion is 2029-06-25.

What conditions does trial NCT07416123 study?

This clinical trial studies the following conditions: Solid Tumors, Urothelial Carcinoma.

What interventions are being tested in trial NCT07416123?

The interventions under investigation include: GEN1106 (BIOLOGICAL).

Who is sponsoring clinical trial NCT07416123?

This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07416123 being conducted?

This trial has 3 study locations across New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Urothelial Carcinoma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.